Posted by Michael Wonder on 23 May 2017
Sanofi and Regeneron announce FDA approval of Kevzara (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients
22 May 2017 - Kevzara is now available to U.S. patients.
Sanofi and Regeneron Pharmaceuticals today announced the U.S. FDA approval of Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying anti-rheumatic drugs, such as methotrexate.
Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), and has been shown to inhibit IL-6R mediated signaling. IL-6 is a cytokine in the body that, in excess and over time, can contribute to the inflammation associated with RA.
